Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT02808858
Recruiting Observational

Italian Network MDS Registry

NCT02808858 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Italiana Sindromi Mielodisplastiche-ETS
Phase
Observational
Started
2013-09
Last updated
2026-09-04

Condition(s) studied

Myelodysplastic-Myeloproliferative Diseases

Study summary

Epidemiological data collection of adult patients affected by myelodysplastic syndrome (MDS) newly diagnosed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
106 Years
Healthy volunteers
No
Inclusion Criteria: * New diagnosis of MDS Exclusion Criteria: * Patient who refuse the signature of informed consent

Primary outcome measure(s)

  • Incidence of MDS diagnosis — 6 years
    Number of new cases every 100.000 person/year
  • Overall Response rate — 6 years
    Proportion of CR or PR after each line of treatment in term of erythroid, platelet and granulocyte response
  • Prevalence of MDS — 6 years
    Number of cases every 100.000 person
  • Overall survival — 6 years
    Time between MDS diagnosis and death due to any causes
  • Progression free survival — 6 years
    Time between MDS diagnosis and relapse/ progression or death due to any causes
  • Progression to AML — 6 years
    Time between MDS diagnosis and Progression to AML or death due to any causes

Trial sites (20)

FacilityCityRegionStatus
Ematologia, AO SS. Antonio e Biagio Alessandria AL Recruiting
Clinica di Ematologia, AOU Ospedale di Torrette Ancona AN Recruiting
U.O. Clinica Medicina Interna, IRCCS San Martino IST Genova GE Recruiting
Struttura Cattedra di Ematologia e CTMO, AOU di Parma Parma PR Recruiting
Ematologia e Centro Trapianti, Centro di Riferimento Oncologico della Basilicata Rionero in Vulture PZ Recruiting
FPO - IRCCS di Candiolo Candiolo Torino Recruiting
S.C.D.U. Ematologia e Terapie cellulari, Ospedale Mauriziano Torino TO Recruiting
Ospedale Cardinal Massaia Asti Italy Recruiting
Ematologia AOU Policlinico di Bari Bari Italy Recruiting
Istituto di Ematologia e Oncologia Medica, Policlinico S.Orsola Bologna Italy Recruiting
Ematologia- Ospedale Businco Cagliari Italy Recruiting
Ospedale Maggiore Chieri Italy Recruiting
Cattedra di Ematologia Policlino Careggi Florence Italy Recruiting
Dipartimento Emato-Oncologia AOU San Martino Genova Genova Italy Recruiting
Medicina interna II Divisione di Ematologia Ospedale S.Luigi Gonzaga Orbassano Italy Recruiting
Azienda Ospedaliera di Padova Padova Italy Recruiting
Azienda Ospedaliera Perugia Perugia Italy Recruiting
AOU San Salvatore Pesaro Italy Recruiting
Ospedale San Giovanbni Battista-Molinette Torino Italy Recruiting
Divisione di Ematologia-Ospedale Cardinale Panico Tricase Italy Recruiting

More Fondazione Italiana Sindromi Mielodisplastiche-ETS trials in Italy

Observational Study on Eltrombopag in Hypocellular Myelodysplastic Neoplasms Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02808858 on ClinicalTrials.gov ↗ ← All trials in Italy